FOXO4-DRI is a modified peptide derived from the Forkhead box protein O4 (FOXO4), which plays a crucial role in cellular stress response and longevity pathways (1, 8). Normally, FOXO4 binds to p53, preventing senescent cells from undergoing apoptosis. FOXO4-DRI functions as a competitive inhibitor, displacing p53 from FOXO4, thereby allowing the selective clearance of senescent cells (2, 9).
Pharmacologically, FOXO4-DRI exhibits:
FOXO4-DRI represents a targeted approach to age-related cellular dysfunction. Studies demonstrate that periodic administration in aged animal models extends healthspan, improving physical performance, organ function, and resistance to age-related diseases (2, 3).
By eliminating senescent cells that accumulate in muscle tissue, FOXO4-DRI restores muscle fiber integrity and enhances regeneration. Research shows significant improvements in muscular endurance and recovery in aging models treated with FOXO4-DRI (4, 10).
Senescent glial cells contribute to neuroinflammation, accelerating cognitive decline. FOXO4-DRI’s ability to remove these cells has shown potential in models of Alzheimer’s disease and other neurodegenerative conditions (5, 11).
By reducing systemic inflammation and improving insulin sensitivity, FOXO4-DRI supports metabolic health, lowering risks associated with type 2 diabetes and cardiovascular disease. Additionally, studies highlight its role in vascular rejuvenation, promoting arterial elasticity and reducing hypertension (6, 7, 13).
**Note:** This product is intended for research purposes only and not for human consumption. Always consult with a healthcare professional before starting any new supplement or research product.